This monoclonal antibody to human CTLA-4 was approved by the Food and Drug Administration (FDA) in 2011 to treat malignant melanoma [3]; this was the first clinical use of an immune checkpoint inhibitor (CPI) in cancer treatment. The gene discussed is CTLA4; the disease is cancer.